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Abstract
Background: Osteoporosis is a major health problem, and the economic burden is expected to rise due to an
increase in life expectancy throughout the world. Current observational evidence suggests that an elevated
homocysteine concentration and poor vitamin B12 and folate status are associated with an increased fracture risk.
As vitamin B12 and folate intake and status play a large role in homocysteine metabolism, it is hypothesized that
supplementation with these B-vitamins will reduce fracture incidence in elderly people with an elevated
homocysteine concentration.
Methods/Design: The B-PROOF (B-Vitamins for the PRevention Of Osteoporotic Fractures) study is a randomized
double-blind placebo-controlled trial. The intervention comprises a period of two years, and includes 2919 subjects,
aged 65 years and older, independently living or institutionalized, with an elevated homocysteine concentration
(≥ 12 μmol/L). One group receives daily a tablet with 500 μg vitamin B12 and 400 μg folic acid and the other
group receives a placebo tablet. In both tablets 15 μg (600 IU) vitamin D is included. The primary outcome of the
study is osteoporotic fractures. Measurements are performed at baseline and after two years and cover bone
health i.e. bone mineral density and bone turnover markers, physical performance and physical activity including
falls, nutritional intake and status, cognitive function, depression, genetics and quality of life. This large multi-center
project is carried out by a consortium from the Erasmus MC (Rotterdam, the Netherlands), VUmc (Amsterdam, the
Netherlands) and Wageningen University, (Wageningen, the Netherlands), the latter acting as coordinator.
Discussion: To our best knowledge, the B-PROOF study is the first intervention study in which the effect of
vitamin B12 and folic acid supplementation on osteoporotic fractures is studied in a general elderly population. We
expect the first longitudinal results of the B-PROOF intervention in the second semester of 2013. The results of this
intervention will provide evidence on the efficacy of vitamin B12 and folate supplementation in the prevention of
osteoporotic fractures.
Trial Registration: The B-PROOF study is registered with the Netherlands Trial (NTR NTR1333) and with
ClinicalTrials.gov (NCT00696514).
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Osteoporosis is a chronic, multifactorial disorder which is
characterized by low bone mass and micro architectural
deterioration of bone tissue [1]. Its major consequence is
fractures, and especially hip fractures are associated with
institutionalization and increased mortality. In 2000,
approximately 9 million fractures occurred worldwide,
leading to a loss of 5.8 million disability adjusted life-years
(DALYs) [2]. Due to a rise in life expectancy, the economic
burden of osteoporotic fractures in Europe is expected to
increase substantially in the coming decades: from €36.3
billion in 2000 to €76.8 billion in 2050 [3].
Pharmacological interventions may prevent 30-60% of
fractures in patients with osteoporosis [4]. However, due
to the high prevalence of osteoporosis and osteoporotic
fractures, attention has been shifted towards preventive
lifestyle interventions, such as vitamin D and calcium sup-
plementation and promoting physical activity. Vitamin D
and calcium supplementation has been shown to decrease
the incidence of hip fractures and other non-vertebral
fractures by 23-26% [5]. Increased physical activity is
related to higher bone mineral density (BMD), bone struc-
ture and elasticity [6,7] and is suggested to reduce the risk
of hip fracture [8].
Besides those well-established factors, it has been shown
that elevated homocysteine concentrations and low vita-
min B12 status are strongly associated with lower bone
mass and higher fracture risk in independent living elderly
[9-11] and frail elderly [12]. Vitamin B12 and folate defi-
ciencies and elevated homocysteine concentrations have
been associated with lower BMD [13-18].
An elevated plasma homocysteine concentration (≥ 15
μmol/L) is prevalent in 30-50% of Dutch people older
than 60 years, increases with age [19-21] and is multifac-
torial; age, sex and lifestyle factors, as well as environmen-
tal and genetic factors, nutritional intake of B-vitamins
and hormonal factors affect homocysteine status [22].
B-vitamins play a central role in the homocysteine meta-
bolism [23]. Treatment with vitamin B12 and folic acid
supplements is effective in normalizing homocysteine con-
centrations [24,25].
Evidence of a beneficial effect of supplementation with
B-vitamins on fracture incidence has been signalled in
Japan in elderly hemiplegic patients following stroke [26].
However, the generalizability of these findings is limited,
since a highly selective patient population with a high per-
centage of vitamin D deficiency and a high fracture risk
was studied. Moreover, pharmacological doses of folic acid
(5 mg/day) and vitamin B12 (1.5 mg/day) were given,
which may increase the risk of adverse effects.
In vitro studies support the hypothesis of a beneficial
effect of vitamin B12 supplementation. Vitamin B12 has
been shown to stimulate osteoblast proliferation and
alkaline phosphatase activity [27] and vitamin B12
deficiency has been associated with defective functional
maturation of osteoblasts [28]. Recent publications indi-
cate a shift to more evidence of osteoclast stimulation
by high homocysteine and low vitamin B12 concentra-
tions [29-31]. These mechanisms might be interrelated
with another, with subsequent interference of homocys-
teine with collagen cross-linking. Cross-links are impor-
tant for stability and strength of the collagen network.
Interference in cross-link formation would cause an
altered bone matrix, further resulting in more fragile
bone [32].
Accordingly, these mechanistic studies support the
hypothesis of a beneficial effect of homocysteine reduc-
tion by B-vitamin supplementation on fracture incidence
and related outcome measures. However, it remains
unknown whether this relationship is causal as evidence
from Randomized Controlled Trials (RCTs) is still lim-
ited. It would be most valuable to assess this relationship
in a population consisting of generally healthy elderly
people as deficiencies of vitamin B12 and folate are highly
prevalent in this population and lead to elevated homo-
cysteine concentrations.
The primary aim of our current intervention is there-
fore to assess the efficacy of oral supplementation with
vitamin B12 and folic acid in the prevention of fractures
in Dutch elderly people with elevated homocysteine con-
centrations. We will address potential pathways and phe-
notypes leading to fractures, osteoporosis measures, falls
and physical performance. We will concurrently address
other outcomes associated with elevated homocysteine
concentrations, such as cognitive function [33] and cardi-
ovascular disease [34]. The aim of this article is to
describe the design of our intervention and to describe
the baseline characteristics of the population enrolled.
Methods/Design
Study design
The B-PROOF study is a randomized, placebo-controlled,
double-blind, parallel intervention study. B-PROOF is an
acronym for ‘B-vitamins for the PRevention Of Osteo-
porotic Fractures’. This large multi-centre project is car-
ried out in The Netherlands by a consortium from
Erasmus MC (EMC, Rotterdam), VU University Medical
Center (VUmc, Amsterdam) and Wageningen University
(WU, Wageningen), the latter acting as coordinator. The
study aimed to include 3000 subjects, aged 65 years and
older, with elevated plasma homocysteine concentrations
(≥ 12 μmol/L). The intervention period is 2 years. Partici-
pants were randomly allocated in a 1:1 ratio to the inter-
vention group or to the control group. We stratified for
study centre, sex, age (65-80 years, ≥ 80 years), and homo-
cysteine concentration (12-18 μmol/L, ≥ 18 μmol/L).
The intervention group receives a daily tablet with 500 μg
vitamin B12 and 400 μg folic acid and the control group
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(600 IU) of vitamin D3 to ensure a normal vitamin D sta-
tus [35]. The intervention and placebo tablets, produced
by Orthica, Almere, the Netherlands, are indistinguishable
in taste, smell and appearance. The random allocation
sequence and randomization were generated and per-
formed using SAS 9.2 by an independent research
dietician.
Recruitment took place from August 2008 until March
2011. The B-PROOF study has been registered with the
Netherlands Trial Register http://www.trialregister.nl
under identifier NTR 1333 since June 1, 2008 and with
ClinicalTrials.gov under identifier NCT00696514 since
June 9, 2008. The WU Medical Ethics Committee
approved the study protocol, and the Medical Ethics com-
mittees of EMC and VUmc gave approval for local
feasibility.
Sample size
Sample size calculation was based on the primary outcome
measure of the intervention, i.e. osteoporotic fractures.
The fracture rate in the non-treated group was estimated
to be 5-6% in a period of two years, based on osteoporotic
fracture incidence in both independently living and insti-
tutionalized elderly. Elderly in the highest quartile of
homocysteine concentrations have been shown to have a
doubled risk of fracture [10], we expected that the fracture
rate in the treated group would be reduced by 34%. With
ap o w e ro f8 0 % ,as i g n i f i c a n c el e v e l( a) of 0.05, one tail,
1500 participants were required for both intervention and
placebo group. To compensate for the expected drop-out
rate of 15%, we extended the intervention period with one
year for the first 600 participants of the study.
Subjects
Most participants were recruited via the registries of
municipalities in the area of the research centres by
inviting all inhabitants aged 65 years and older by mail.
Furthermore, inhabitants of elderly homes in the area of
Rotterdam, Amsterdam and Wageningen were invited to
participate, after providing information brochures and
information meetings. In addition, elderly who partici-
pated in previous studies of the research centres were
approached. All participants gave written informed con-
sent before the start of the intervention.
A total of 2919 subjects were included in the interven-
tion (Figure 1). Inclusion and exclusion criteria are listed
in Table 1.
Changes to inclusion criteria after trial commencement
The inclusion criteria regarding cut-off values for
plasma homocysteine concentrations and age were
adapted during the first phase of the intervention. The
initial eligibility criterion for plasma homocysteine
concentrations has been adjusted from ≥ 15 μmol/L to
≥ 12 μmol/L before the start of the study. Extended data
analyses (unpublished data), based on Van Meurs et al.,
2004, showed that a relation between homocysteine sta-
tus and fracture incidence is also present at a lower
homocysteine concentration (~14 μmol/L). Furthermore,
cross-calibration between different local homocysteine
methods used in the current study (Architect Analyser,
HPLC and LC-MS) and the methods used in the pre-
vious leading studies [9,10] showed that a homocysteine
concentration of 14 μmol/L in these studies corre-
sponded with a concentration of 12 μmol/L when using
the current methods.
It was decided to adapt the criterion for age from 70
years and older to 65 years and older after the first year
of recruitment, because the association between homo-
cysteine and fractures is also present in people aged 65-
70 years [9,10].
Screening and run-in period
Blood samples were obtained from participants in the
morning at the research centres or at an external loca-
tion in the living area of the participants. Participants
were in a fasted state, or had taken a light breakfast.
Venous blood was drawn by a skilled nurse to obtain
plasma, serum and buffy coats. For homocysteine analy-
sis, a plasma EDTA tube was stored on ice immediately
after blood drawing and samples were processed within
4 hours after blood drawing, to prevent a temperature-
and time-dependent increase in plasma homocysteine
[36]. Plasma homocysteine was measured using the
Architect i2000 RS analyser (VUmc, intra assay CV =
2%, inter assay CV = 4%), HPLC method [37] (WU,
intra assay CV = 3.1%, inter assay CV = 5.9%) and LC-
MS/MS (EMC, CV = 3.1%). According to a cross-cali-
bration, outcomes of the three centres did not differ sig-
nificantly. Serum creatinine was measured with the
enzymatic colorimetric Roche CREA plus assay (CV =
2%). The remaining plasma, serum and buffy coats sam-
ples were kept frozen at -80°C until further analysis.
After blood sampling participants started with a six-
week run-in period, in which the participants took pla-
cebo tablets and were asked to daily fill out their study
supplement intake on a research calendar. Subsequently,
participants were informed whether they could further
participate in the study or not, as an elevated plasma
homocysteine concentration was an inclusion criterion,
and an elevated serum creatinine concentration was an
exclusion criterion. In case of laboratory results outside
the reference range set for homocysteine (> 50 μmol/L)
or creatinine (> 150 μmol/L) participants were referred
to their general practitioner.
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Eligible participants were invited for baseline measure-
ments, which were performed during a 1.5-2 hour ses-
sion at one of the study centres or at the participant’s
home. The 2-year intervention period started after these
baseline measurements. Adherence was assessed by
recordings on the research calendar, counts of bi-
annually returned tablets, and periodical phone calls
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Figure 1 Recruitment and baseline measurements in participants of the B-PROOF study.
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participants are invited for follow-up measurements, in
which the baseline measurements are repeated.
Primary outcome
The primary outcome of the trial is time to first osteo-
porotic fracture. Participants recorded fractures on the
research calendar, which was returned every 3 months.
Incomplete or unclear data were further inquired by tele-
phone. Furthermore, the research team verified reported
fractures with the participants’ general practitioner, hospi-
tal physician and/or by radiographs. All fractures are con-
sidered osteoporotic, except for head/hand/finger/foot/toe
fractures and fractures caused by traffic accidents [38].
The time to fracture is the difference between starting
date and date of fracture reported on the calendar or by
the general practitioner.
Secondary outcomes
Falls
Falls were recorded weekly on the research calendar. A
fall was defined as an unintentional change in position
resulting in coming to rest at a lower level or on the
ground [39]. Recurrent falling was defined as at least two
falls of a participant within six months during the two
years of follow-up [40].
Dual Energy X-ray Assessment (DXA)
In two out of three study centres Dual Energy X-ray
Assessment (DXA) was performed to measure bone
mineral density (BMD) and lean body mass and to assess
vertebral fractures, using the Hologic QDR 4500 Delphi
device (VUmc, Hologic Inc., USA, CV = 0.45%) or the GE
Lunar Prodigy device (EMC, GE Healthcare, USA, CV =
0.08%). The two devices were cross-calibrated. DXA was
performed under standard protocols within four weeks
after the participant’s start of the intervention.
Total hip, femoral neck and lumbar spine BMD (g/cm
2)
were measured. Total hip BMD was measured at the left
femur, while in case of a hip prosthesis at the left side, the
right side was measured. Instant vertebral assessment
(IVA) was performed to detect clinical and non-clinical
vertebral fractures. Results were independently evaluated
by two researchers, and inconsistencies were discussed.
Furthermore, total body composition was measured.
The amount of fat-free soft tissue (i.e. lean mass minus
bone mineral content) of the extremities can be used as
an indicator of skeletal muscle mass and has been vali-
dated in older persons [41].
Quantitative Ultrasound (QUS)
Quantitative ultrasound (QUS) measurements of the cal-
caneus were performed using a Hologic Sahara bone den-
sitometer (Hologic Inc., USA). Broadband ultrasound
attenuation (BUA, dB/MHz, CV = 3.7%) and speed of
sound (SOS, m/s, CV = 0.22%) were measured in duplicate
in both the right and the left calcaneus. From these para-
meters, the quantitative ultrasound index (QUI, CV =
2.6%) and estimated BMD (eBMD) were calculated.
Bone turnover markers
After completion of the study, bone turnover markers
will be determined in a subsample in order to obtain bet-
ter insight in the mechanism underlying the effect of B-
vitamin supplementation on bone health. Standard assays
will be performed in baseline and follow-up blood sam-
ples to measure markers of bone formation and bone
resorption, such as procollagen type 1 N-extension pep-
tide (P1NP) and cross-linked carboxyterminal telopeptide
of type 1 collagen (CTx).
Physical performance and handgrip strength
Physical performance was measured using three tests; a
walking test, a chair stands test, and a balance test.
These performance tests are commonly used in elderly
people [42-44]. During the timed walking test, partici-
pants were asked to walk 3 meters, turn around, and
walk back as quickly as possible. During the timed chair
stands test the participants rose from and sat down in a
chair as quickly as possible for five consecutive times
without the use of their arms. Standing balance was
assessed with the modified Romberg test in which the
participants were asked to maintain balance for 10 sec-
onds in four different positions with increasing diffi-
culty. Each position was performed with eyes open and
eyes closed.
Hand grip strength (kg) was measured using a strain-
gauged dynamometer (Takei, TKK 5401, Takei Scientific
Instruments Co. Ltd., Japan, inter observer CV = 5%).
Participants were asked to perform two maximum hand
Table 1 inclusion and exclusion criteria for the B-PROOF study
Inclusion criteria: Exclusion criteria:
Men and women, aged 65 years and older Immobilization: being bedridden or wheelchair bound
Compliance for tablet intake of > 85% 4-6 weeks
prior to start of the trial
Cancer diagnosis within the last 5 year, except skin cancer as basal cell carcinoma and
squamous cell carcinoma
Competent to make own decisions Serum creatinine level > 150 μmol/L
Elevated homocysteine level (≥ 12 μmol/L and ≤
50 μmol/L)
Current or recent (< 4 months) use of supplements with very high doses of vitamin B12
(intramuscular injections) or folic acid (> 300 μg)
Participation in other intervention studies
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Page 5 of 10grip trials with each hand in standing position with their
arms along their body. Maximal hand grip strength was
defined as the average of the highest score of the left
and right hand.
Vascular parameters
Blood pressure measurements were performed using an
Omron M1 plus blood pressure device (Omron Health-
care Europe). In two of the centres vascular structure
and function was assessed non-invasively in a subsample
by measuring blood pressure, intima-media-thickness
(IMT) of the carotid artery, carotid distensibility (DC),
aortic pulse wave velocity (PWV) and augmentation
index (AIx).
Carotid B-mode ultrasonography is performed using the
L105 40 mm 7.5 MHz array transducer (Picus, Pie Medical
Equipment, Maastricht, the Netherlands) on the right car-
otid artery. IMT is evaluated as the distance luminal-
intimal interference and the media-adventitial interface
(Art.Lab, Esoate Europe, Maastricht, the Netherlands).
The vessel wall movement-detector system has been
described in detail previously [45]. The system consists of
a wall track system and data-acquisition system (Art.Lab,
Esoate Europe, Maastricht, the Netherlands). AIx is calcu-
lated using arterial tonometry obtained from the right
radial, carotid and femoral artery using the Sphygmocor
device (Sphygmocor version 7.1, AtCor Medical, Sydney,
Australia). PWV is measured with simultaneously three
channel ECG recording and recording of the right carotid
and femoral artery pulse waveforms. Twenty-four hour
ambulatory blood pressure recording was performed using
Oscar 2 ambulatory 24 hour blood pressure monitor (Sun-
Tech Medical, North Carolina, USA).
Biomarkers of cardiovascular disease and cardiovascular
events
Cardiovascular events were defined as cardiovascular
mortality, myocardial infarction and stroke. Participants
were requested to fill out a questionnaire regarding their
cardiovascular history. After completion of the study car-
diovascular and inflammatory biomarkers, such as
amino-terminal B-type natriuretic peptide (NT-proBNP)
and high-sensitivity hsC-reactive protein (hs-CRP) will be
measured in baseline and follow-up blood samples.
Cognitive function
We used the Mini-Mental State Examination (MMSE) for
a description of global cognitive performance in our
study population [46]. In a subsample, i.e. all participants
of WU, domain specific cognitive function was assessed
using six standardized tests; the Symbol Digit Modalities
Test, the Letter Fluency test, the Trail Making Test, the
Digit Span Test, the Word Learning Test and the Stroop
Colour Word Test. These tests were used to construct
the following cognitive domains: attention, working
memory, executive function, information processing
speed and episodic memory [47].
Depression and Quality of Life
The Geriatric Depression Scale (GDS) was used to mea-
sure depressive symptoms [48]. To determine quality of
life the EuroQoL EQ-5D [49] and Short Form Health
Survey (SF-12) [50] questionnaires were used.
Measurement of covariates
General self-reported health and medication usage
Self-reported medical history, ethnicity, use of medication
and of nutritional supplements, current alcohol intake and
smoking habits and history of falls and fractures were
determined using a questionnaire.
Medication use during the study period was also
retrieved from pharmacies. Data included the prescription
period, the total amount of drug units per prescription,
the prescribed daily number of units, product name, and
the Anatomical Therapeutic Chemical (ATC) code.
Physical Activity
Physical activity was measured using the LASA Physical
Activity Questionnaire (LAPAQ), which is a validated
questionnaire to measure physical activity in elderly peo-
ple [51]. The activities included walking, cycling, garden-
ing, participation in sports and light and heavy household
activities. Frequency and duration of each activity during
the last two weeks were assessed. Physical activity was
calculated in minutes/day and kcal/day.
Nutritional status and food intake
The Mini Nutritional Assessment (MNA) [52] and the
Simplified Nutritional Appetite Questionnaire (SNAQ)
[53] were used to screen for malnutrition and appetite
loss. Standing height was measured in duplicate to the
nearest 0.1 cm with the person standing erect and wearing
no shoes. Weight was measured to the nearest 0.5 kg with
the person wearing light garments without shoes and
empty pockets. In a subsample, i.e. all participants of WU,
we estimated dietary intake by a Food Frequency Ques-
tionnaire (FFQ) with its main focus on macronutrients,
vitamin B12, folate, vitamin D, and calcium. The FFQ was
developed by the dietetics group at the department of
Human Nutrition, Wageningen University and was
derived from an FFQ which was validated for energy, fat,
cholesterol, folate and vitamin B12 intake [54,55].
Genotyping
From the blood samples drawn at baseline, DNA was iso-
lated for genotyping. Subsequently, all samples were gen-
otyped for approximately 700.000 single nucleotide
polymorphisms (SNPs) using the Illumina Omni-express
array, which has > 90% coverage of all common variation
in the genome. If known functional SNPs were not
tagged well by the array, they were genotyped separately
using TaqMan allelic discrimination assays on the ABI
Prism 9700 HT sequence detection system. The data will
be used in a hypothesis-free genome-wide association
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in known candidate genes.
Data analysis
T h ed a t aa n a l y s e sw i l lb ep e r f o r m e db yf o l l o w i n gt h e
intention-to-treat procedure (effectiveness study) and
the per-protocol-procedure (efficacy study). If necessary,
data will be transformed and analyses will be adjusted
for the presence of covariates. Time to first fracture will
be analysed using Cox Proportional Hazard Models.
Differences in mean change between groups will be
analysed with independent sample Student’st - t e s t ,
ANOVA or other similar tests.
Two-sided P values will be calculated and a signifi-
cance level of 0.05 will be applied.
We did not perform an interim analysis because we
did not expect and observe negative side effects of the
supplementation and because of the relatively long
recruitment period, with most of the participants
included in the last year of recruitment. We keep track
of any serious adverse events (SAEs) occurring during
the duration of the study.
Inclusion and baseline characteristics of the participants
Baseline characteristics of participants in the B-PROOF
study are shown in Table 2. During the recruitment, we
addressed approximately 69.000 people (Figure 1). This
resulted in the screening of 6242 interested persons, of
which 3027 were eligible to participate. One hundred and
eight participants withdrew consent before start of the
intervention resulting in 2919 participants who com-
pleted baseline measurements. The mean age of partici-
pants at the start of the intervention was 74.1 years (SD:
6.5) and 50% was female. Median plasma homocysteine
concentration was 14.1 μmol/L (IQR: 13.0-16.6).
Discussion
To our best knowledge, the B-PROOF study is the first
intervention study in which the effect of vitamin B12 and
folic acid supplementation on osteoporotic fractures is stu-
died in a general elderly population. Currently, folic acid
fortification is not mandatory in the Netherlands, and it is
only applied on small scale in bread substitutes. This inter-
vention is therefore an excellent opportunity to investigate
the effect of folic acid and vitamin B12 supplementation in
a non-fortified population. Positive evidence emerging
from this intervention might enable elderly to live into an
advanced age with lower fracture risk. Implementation of
vitamin B12 and folic acid supplementation might there-
fore reduce the costs of national health services for osteo-
porosis in the elderly.
Elevated homocysteine concentrations are associated
with various health outcomes, but until now there are no
large interventions investigating the effect of homocysteine
lowering treatment on, for example, physical performance.
Therefore, the wide range of secondary outcomes studied
in the B-PROOF study is unique. The possibility to per-
form a GWAS in such a large general elderly population
will provide us with relevant data on the underlying
mechanisms and genes involved in age-related diseases as
Table 2 Baseline characteristics of the B-PROOF study participants
Total (n = 2919) Male (n = 1456) Female (n = 1463)
Study location (n)
-WU 856 499 357
-VUmc 778 301 477
-Erasmus MC 1285 656 629
Age (years)* 74.1 (6.5) 73.4 (6.1) 74.9 (6.8)
Plasma homocysteine (μmol/L)
# 14.4 14.6 14.1
[13.0-16.6] [13.1-16.8] [12.9-16.3]
Serum creatinine (μmol/L)
# 82.0 90.0 73.0
[71-94] [81.0-101.0] [65.0-84.0]
Weight (kg)
# 77.9 (13.3) 83.1 (11.9) 72.7 (12.5)
Height (cm)
# 169.3 (9.3) 175.9 (6.6) 162.7 (6.6)
Physical activity (min/day)
# 130.0 116.3 142.9
[84.0-192.9] [72.5-177.0] [96.0-205.7]
Years of education* 10.1 (4.0) 10.9 (4.1) 9.2 (3.6)
Smoking (%)
- Current 9.6 10.8 8.5
- Former 56.5 69.1 44.0
- Never 33.9 20.1 47.6
*Results are presented in mean (standard deviation);
#Results are presented in median [interquartile range].
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lysis gives us the opportunity to focus on the effect of B-
vitamins on epigenetic changes.
We have some remarks on the expected outcomes of
this study. We expect the effect of folic acid and vitamin
B12 supplementation to be most beneficial in people with
an elevated homocysteine concentration. We therefore
only included elderly people with elevated homocysteine
concentrations (≥ 12 μmol/L), but as a consequence, we
cannot extrapolate the results to elderly with low to nor-
mal homocysteine concentrations (< 12 μmol/L). How-
ever, 49% of the elderly screened in our study had an
elevated homocysteine concentration. This percentage
might be higher in the general Dutch elderly population,
since people interested in nutrition and health, with a sub-
sequent healthier lifestyle are probably more willing to
participate in a long term intervention study. Therefore,
the B-PROOF study covers a large segment of the general
Dutch elderly population.
Because we supply both folic acid and vitamin B12,i tw i l l
not be possible to indicate whether the effects of the inter-
vention will be the consequence of folic acid or vitamin
B12 supplementation or lowering homocysteine concentra-
tions in general. However, since both vitamins play a sig-
nificant role in homocysteine metabolism, and folic acid
supplementation alone might mask a possible vitamin B12
deficiency [56], it is the most efficient and safest to supple-
ment both vitamins.
The first longitudinal results of the B-PROOF study
will become available in the second semester of 2013.
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